Prospective Multicenter Observational Study of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Starting Second- or Third-line Therapy and not Receiving Autologous Stem Cell Transplant.

Criteria: Inclusion Criteria:

1. Age ≥18 years at the time of diagnosis of R/R DLBCL

2. Initiated or initiating tafasitamab treatment

3. R/R DLBCL patients who have received at least one (1) prior line of treatment for

DLBCL

4. Histologically confirmed DLBCL such as:

a) DLBCL not otherwise specified (NOS) b) T-cell histiocyte-rich large B-cell lymphoma

(THRLBCL) c) Epstein-Barr virus (EBV)-positive DLBCL of the elderly d) Composite

lymphoma with a DLBCL component with a subsequent DLBCL relapse, according to Revised

European American Lymphoma (REAL)/World Health Organization (WHO) classification e)

Patients with evidence of histological transformation to DLBCL from an earlier

diagnosis of low-grade lymphoma (i.e., an indolent pathology such as follicular

lymphoma [FL], marginal zone lymphoma [MZL], chronic lymphocytic leukemia [CLL]) with

a subsequent DLBCL relapse f) High-grade B-cell lymphoma: i) DLBCL with MYC and BCL2

or BCL6 translocation (double-hit) and MYC and BCL2 and BCL6 translocations

(triple-hit) ii) High-grade B-cell lymphoma, NOS

5. Signed and dated ICF by the patient or the patient's Legally Acceptable Representative

(LAR), for patients with prospective data collection, as applicable. For deceased or

otherwise unreachable patients, no informed consent will be obtained for data

collection in the study, provided that the competent Independent Ethics Committee

(IEC)/Institutional Review Board (IRB) has provided favorable opinion and that any

other local regulatory requirements on this matter are met

Exclusion Criteria

• Initiated or initiating tafasitamab treatment in the context of an interventional study.